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Clinical PerspectiveWhat Is New?In a contemporary population of patients treated with primary percutaneous coronary intervention, early (before 1 year) cessation of prasugrel treatment was not uncommon and more frequently consisted of switching to clopidogrel.Early prasugrel cessation was associated with significantly increased risk of downstream ischemic events only in the context of disruption (ie, premature cessation because of bleeding, side effects, or patient noncompliance).What Are the Clinical Implications?The increased risk of subsequent ischemic events should be considered when prasugrel is stopped early because of a bleeding event or noncompliance.Future studies should explore whether shorter than currently recommended duration of prasugrel treatment might be an acceptable option in properly selected patients with ST‐segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

 {#jah33138-sec-0008}

Flow restoration in the infarct‐related artery by means of percutaneous coronary intervention (PCI) and dual antiplatelet therapy (DAPT) for potent platelet inhibition are the cornerstones for management of patients with acute ST‐segment--elevation myocardial infarction (STEMI).[1](#jah33138-bib-0001){ref-type="ref"}, [2](#jah33138-bib-0002){ref-type="ref"} Compared with clopidogrel, prasugrel provides rapid‐onset, more potent and consistent inhibition of platelet aggregation,[3](#jah33138-bib-0003){ref-type="ref"} and reduces the risk of cardiovascular mortality and stent thrombosis in patients with myocardial infarction (MI).[4](#jah33138-bib-0004){ref-type="ref"} Prasugrel is recommended over clopidogrel following primary PCI[1](#jah33138-bib-0001){ref-type="ref"}, [2](#jah33138-bib-0002){ref-type="ref"} and is used increasingly in real‐world clinical practice.[5](#jah33138-bib-0005){ref-type="ref"}

Nonadherence to recommended antiplatelet therapy following PCI is not uncommon and increases the risk of adverse ischemic events.[6](#jah33138-bib-0006){ref-type="ref"}, [7](#jah33138-bib-0007){ref-type="ref"}, [8](#jah33138-bib-0008){ref-type="ref"} Notably, different modes of DAPT cessation (either driven by physician recommendation, patient noncompliance, or interventions necessitating temporary treatment withdrawal) appear to have varying effects on patient outcomes.[6](#jah33138-bib-0006){ref-type="ref"} Previous studies assessing premature cessation of antiplatelet therapy focused primarily on more stable clinical settings and clopidogrel rather than novel, potent P2Y~12~‐inhibitors, and they often did not account for the temporal relation between treatment cessation and subsequent outcomes.[9](#jah33138-bib-0009){ref-type="ref"}, [10](#jah33138-bib-0010){ref-type="ref"} While STEMI is characterized by elevated ischemic risk compared with stable coronary artery disease (CAD) and is an independent predictor of stent thrombosis,[11](#jah33138-bib-0011){ref-type="ref"} there are limited data on the adherence to guideline‐recommended antiplatelet treatment following primary PCI. Moreover, although certain aspects of prasugrel treatment might adversely affect long‐term compliance, including greater treatment cost or accentuated risk of bleeding, little is known about adherence to prasugrel in patients with STEMI. Against this background, we sought to address the incidence, underlying reasons, and clinical impact of early prasugrel cessation in a sizable, contemporary cohort of patients with STEMI treated by current standards (ie, primary PCI with predominantly new‐generation drug‐eluting stents \[DES\]).

Methods {#jah33138-sec-0009}
=======

The data, analytic methods, and study materials cannot be made available to other researchers for purposes of reproducing the results or replicating the procedure, given constraints in broader sharing of the data.

Patient Population {#jah33138-sec-0010}
------------------

For the present study, we pooled patients with STEMI with the same qualifying diagnostic criteria who were included in the prospective Bern PCI Registry (NCT02241291), SPUM‐ACS (Inflammation and Acute Coronary Syndromes) registry (NCT01000701), or COMFORTABLE‐AMI (Comparison of Biomatrix Versus Gazelle in ST‐Elevation Myocardial Infarction (STEMI)) trial (NCT00962416); were treated by means of PCI; and discharged on prasugrel. Details are presented in Data [S1](#jah33138-sup-0001){ref-type="supplementary-material"}. Briefly, all patients undergoing PCI at Bern University Hospital, Switzerland as of 2009 have been prospectively entered into the Bern PCI Registry.[12](#jah33138-bib-0012){ref-type="ref"}, [13](#jah33138-bib-0013){ref-type="ref"} There are no formal exclusion criteria, and all patients providing informed consent for prospective follow‐up are included. The SPUM‐ACS cohort study is a multicenter, observational cohort study of patients presenting with acute coronary syndromes (ACS) at 4 Swiss tertiary centers with minimal exclusion criteria (severe physical disability, inability to comprehend study requirements, and estimated life expectancy \<1 year).[14](#jah33138-bib-0014){ref-type="ref"} The COMFORTABLE AMI trial was a multicenter, randomized controlled trial (RCT) comparing a biodegradable polymer--based biolimus‐eluting stent with a bare‐metal stent for primary PCI. Main exclusion criteria were mechanical complications of acute MI, use of vitamin‐K antagonists, planned surgery (unless uninterrupted DAPT during the perisurgical period was judged feasible), and history of bleeding diathesis.[15](#jah33138-bib-0015){ref-type="ref"} The studies complied with the Declaration of Helsinki and were approved by local institutional ethics committees. All patients provided written, informed consent.

Procedures {#jah33138-sec-0011}
----------

PCI was performed in accordance with current practice guidelines.[2](#jah33138-bib-0002){ref-type="ref"} Thrombus aspiration was recommended in all patients whenever deemed technically feasible (COMFORTABLE‐AMI) or whenever thrombus was angiographically visible (registry patients). In the COMFORTABLE‐AMI trial, patients were randomly assigned to treatment with biolimus‐eluting stents (BioMatrix, Biosensors Europe SA, Morges, Switzerland) or bare‐metal stent (Gazelle, Biosensors Europe SA). In registry patients, the use of a newer‐generation DES was recommended with final selection of stent type left at the discretion of the operator. Periprocedural management, including dose of unfractionated heparin or use of glycoprotein IIb/IIIa inhibitors, was left to the operators' discretion. DAPT consisting of aspirin and a P2Y~12~‐inhibitor was initiated before, at the time of, or immediately after the procedure. The recommended treatment duration was 1 year for prasugrel and lifelong treatment for aspirin for both RCT and registry patients. Prasugrel administration was discouraged in patients with prior cerebrovascular events. Recommended maintenance dose for prasugrel was 10 mg, or 5 mg in patients with age \>75 years or body weight \<60 kg.

Patient Follow‐Up {#jah33138-sec-0012}
-----------------

Patients were prospectively followed throughout 1 year after PCI to assess adverse cardiac and cerebrovascular events in all 3 studies. Survival data were obtained from hospital records and municipal civil registries. A health questionnaire was sent to all living patients with questions on rehospitalization, medical treatment, and adverse events, followed by telephone contact in case of missing response. General practitioners, referring cardiologists, and patients were contacted, and external medical records, discharge letters, and coronary angiography documentation were systematically reviewed for additional information in case of potential events or any change in P2Y~12~‐inhibitor therapy. Independent study monitors verified source data according to a prespecified monitoring plan. Identical case record forms were used for all patients in the 2 registries as well as the RCT, and all data were stored in the same central database (Cardiobase, 2mT, Ulm, Germany). Medical treatment was recorded during index PCI, at discharge, and at 1 year. Adherence to prasugrel, date, and patient‐reported reasons for cessation were specifically assessed via telephone interview or clinical visit at 1 year; in addition, all medical reports were screened for medication status. Because protocol‐recommended duration of P2Y~12~‐inhibitor treatment was ≈1 year (unless recurrent ischemic events triggered longer continuation), we considered 330 days or more of treatment as adherence.

Adjudication of cessation events was done centrally for all patients included in the pooled data set. Prespecified categories of prasugrel treatment status at 1 year included no cessation (continuous 1‐year treatment) or cessation (any stop before 1 year). Cessation was classified as (1) crossover to another P2Y~12~‐inhibitor (clopidogrel or ticagrelor); (2) physician‐recommended discontinuation (because of initiation of oral anticoagulation, surgery/intervention, or unspecified physician decision); and (3) disruption because of bleeding, perceived side effects, or patient noncompliance. Discontinuation and disruption were defined similarly to the PARIS (Patterns of Non‐Adherence to Antiplatelet Regimens in Stented Patients) study.[6](#jah33138-bib-0006){ref-type="ref"} Because of the potential for de‐escalation from prasugrel to a less‐potent antiplatelet agent, we also recorded crossover that was not reported in PARIS (which included 92% clopidogrel‐treated patients). Moreover, because timing of possible re‐initiation of prasugrel was not captured in this population, we were unable to define interruptions (defined as cessation for up to 14 days because of surgery in PARIS); temporary cessations because of surgery or other interventions were included under physician‐decided discontinuation in our analysis. First cessation events are reported, such that some patients with cessation were receiving prasugrel at 1 year because of subsequent re‐initiation.

Clinical End Points and Study Assessments {#jah33138-sec-0013}
-----------------------------------------

Clinical events were adjudicated by an independent clinical events committee for each study. Because 1 center (Bern University Hospital, Bern, Switzerland) had the leading role for planning, coordination, and execution of all 3 studies, outcome definitions were identical and event adjudication was done in a consistent, comparable manner for all patients included in the 3 studies. Cardiac death was defined as any death from an immediate cardiac cause, procedure‐related mortality, and death of unknown cause. Definitions of spontaneous and periprocedural MI are detailed in Data [S1](#jah33138-sup-0001){ref-type="supplementary-material"}. Stent thrombosis was defined according to the Academic Research Consortium definitions.[16](#jah33138-bib-0016){ref-type="ref"} Bleeding was categorized according to Bleeding Academic Research Consortium as well as Thrombolysis in Myocardial Infarction criteria.[17](#jah33138-bib-0017){ref-type="ref"} For the present analysis, the primary end point was a composite of cardiac death, nonfatal MI, and stroke. The key secondary end point was the composite of cardiac death, MI, stroke, target‐vessel revascularization, and definite or probable stent thrombosis.

Statistical Analyses {#jah33138-sec-0014}
--------------------

Continuous variables are summarized as mean±SD and categorical ones as numbers (percentages). *P* values for between‐group comparisons are based on *t* tests, Fisher exact tests, and χ^2^ tests as appropriate. Lesion characteristics were compared using mixed linear, logistic, and multinomial regression models accounting for multiple lesions per patient. Kaplan--Meier curves were constructed for time to prasugrel cessation. Predictors of early prasugrel cessation were modeled using Cox models and those predictors with significant relationship (*P*\<0.2) were evaluated for inclusion into a multivariate model; predictors with *P*\<0.15 inside the multivariable model were finally retained. Using Cox models with time‐varying covariates, we examined the effect of prasugrel cessation on clinical outcomes. For patients with any of the 3 types of early cessation (discontinuation, crossover, or disruption), the follow‐up time was split into 2 periods, before versus after the first recorded given type of cessation; events occurring in patients without cessation or before treatment cessation were used as reference, and no other covariates were included. Results are presented as hazard ratios (HR) with corresponding 95% confidence intervals (CI). For all clinical events, expected numbers were calculated as number of events divided by the HR (compared with the reference of being on prasugrel treatment). Analyses were performed in Stata 14.2.

Results {#jah33138-sec-0015}
=======

Baseline Characteristics {#jah33138-sec-0016}
------------------------

Of all 4454 patients with STEMI enrolled between October 2009 and June 2014, 1953 were discharged on prasugrel and 1830 patients were finally included in the present analysis (Figure [1](#jah33138-fig-0001){ref-type="fig"}). Clinical follow‐up at 1‐year post‐PCI was available for all but 3 patients (Table [S1](#jah33138-sup-0001){ref-type="supplementary-material"}). Within 1 year, any cessation of prasugrel had occurred in 252 patients (13.8%). Patterns of cessation included crossover (7.2%), physician‐recommended discontinuation (3.7%), and disruption (2.9%). Crossover included switching primarily to clopidogrel or, less frequently, ticagrelor (83.1% versus 8.5% of patients in the crossover group were on clopidogrel versus ticagrelor at 1 year, respectively; Table [S2](#jah33138-sup-0001){ref-type="supplementary-material"}). The time course of different types of prasugrel cessation is summarized in Figure [2](#jah33138-fig-0002){ref-type="fig"}, indicating earlier crossover versus more delayed discontinuation or disruption (median time with 25% to 75% interquartile range 31 \[10--115\] versus 207 \[120--291\] versus 158 \[62--250\] days, respectively).

![Summary of study flow. APT indicates antiplatelet therapy; PCI, percutaneous coronary intervention; STEMI, ST‐segment--elevation myocardial infarction.](JAH3-7-e008085-g001){#jah33138-fig-0001}

![One‐year Kaplan--Meier plots of crossover, physician‐recommended discontinuation, and disruption of prasugrel throughout 1 year.](JAH3-7-e008085-g002){#jah33138-fig-0002}

Baseline characteristics are summarized in Table [1](#jah33138-tbl-0001){ref-type="table"}. Compared with patients with no early cessation, those with crossover to clopidogrel or ticagrelor were older, more frequently female with a history of cerebrovascular event, and less frequently had insulin‐treated diabetes mellitus. Moreover, history of malignancy and anemia were more frequent in patients with discontinuation. We found no substantive differences with respect to professional background, marital status, and educational level (Table [S3](#jah33138-sup-0001){ref-type="supplementary-material"}). Patients with crossover were more commonly treated with new‐generation DES and less frequently with bare‐metal stent (Table [2](#jah33138-tbl-0002){ref-type="table"}). Independent predictors of any early cessation included female sex, history of cerebrovascular event, and age (Table [3](#jah33138-tbl-0003){ref-type="table"} and Table [S4](#jah33138-sup-0001){ref-type="supplementary-material"}).

###### 

Baseline Clinical Characteristics

                                                             No Cessation (n=1578)   Crossover (n=131)   Discontinuation (n=67)   Disruption (n=54)   *P* Value (vs No Cessation)           
  ---------------------------------------------------------- ----------------------- ------------------- ------------------------ ------------------- ----------------------------- ------- ------
  Age                                                        58.9±10.7               61.2±11.5           60.9±13.3                59.9±11.7           0.02                          0.14    0.49
  Female sex                                                 247 (15.7)              38 (29.0)           20 (29.9)                7 (13)              \<0.001                       0.004   0.71
  BMI                                                        27.4±4.2                26.8±4.0            26.3±4.4                 27.2±4.3            0.11                          0.04    0.66
  Current smoking                                            748 (48.0)              58 (44.3)           28 (43.8)                28 (52.8)           0.47                          0.53    0.58
  Hyperlipidemia                                             799 (51.1)              75 (57.3)           36 (53.7)                25 (47.2)           0.20                          0.71    0.58
  Hypertension                                               733 (46.6)              65 (49.6)           23 (34.3)                19 (35.2)           0.52                          0.06    0.13
  Diabetes mellitus                                          212 (13.5)              11 (8.4)            6 (9)                    6 (11.1)            0.11                          0.36    0.84
  Insulin‐dependent                                          50 (3.2)                0 (0)               2 (3.0)                  2 (3.7)             0.03                          1.00    0.69
  Family history of CAD                                      403 (25.9)              37 (28.5)           14 (20.9)                8 (15.1)            0.53                          0.39    0.08
  Renal dysfunction[a](#jah33138-note-0004){ref-type="fn"}   113 (8.1)               12 (10.4)           7 (10.9)                 3 (6.3)             0.38                          0.36    1.00
  Peripheral artery disease                                  35 (2.2)                2 (1.5)             0 (0)                    1 (1.9)             1.00                          0.40    1.00
  History of cerebrovascular event                           9 (0.6)                 4 (3.1)             1 (1.5)                  0 (0)               0.01                          0.34    1.00
  Previous PCI                                               135 (8.6)               11 (8.4)            2 (3.0)                  3 (5.6)             1.00                          0.12    0.62
  Previous CABG                                              27 (1.7)                1 (0.8)             0 (0.0)                  0 (0)               0.72                          0.62    1.00
  Time from symptom onset to balloon inflation (min)         226 (159; 385)          244 (157; 465)      259 (165; 562)           228 (156; 377)      0.38                          0.09    0.95
  Killip class IV at presentation                            76 (4.8)                8 (6.2)             3 (4.5)                  0 (0)               0.52                          1.00    0.18
  LVEF (%)                                                   48.0±11.1               46.4±11.6           44.4±12.0                51.1±9.2            0.16                          0.02    0.06
  History of malignancy                                      66 (4.2)                0 (0)               10 (14.9)                4 (7.4)             0.008                         0.001   0.29
  Anemia[b](#jah33138-note-0005){ref-type="fn"}              162 (12.3)              13 (11.7)           12 (21.1)                1 (2.4)             1.00                          0.06    0.05
  Thrombocytopenia[c](#jah33138-note-0006){ref-type="fn"}    32 (2.4)                1 (0.9)             1 (1.8)                  1 (2.4)             0.51                          1.00    1.00

Data are summarized as mean±SD, median (25--75% interquartile range), or count (%). BMI indicates body mass index; CABG, coronary artery bypass graft; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention.

Defined as estimated glomerular filtration rate \<60 mL/min per 1.73 m² using the Cockcroft‐Gault formula.

Hemoglobin \<130 g/L for men or \<120 g/L for women.

Thrombocytes \<150 g/L.

###### 

Procedural Characteristics

                                                                    No Cessation (n=1578)   Crossover (n=131)   Discontinuation (n=67)   Disruption (n=54)   *P* Value (vs No Cessation)          
  ----------------------------------------------------------------- ----------------------- ------------------- ------------------------ ------------------- ----------------------------- ------ ------
  Number of lesions                                                 2219                    189                 99                       82                                                       
  Lesions treated per patient                                       1.41±0.73               1.44±0.81           1.48±0.81                1.52±0.77           0.59                          0.40   0.27
  Multivessel treatment                                             174 (11.)               17 (13)             10 (15.2)                8 (14.8)            0.47                          0.32   0.38
  Treated vessels                                                                                                                                                                                 
  Left main coronary artery                                         28 (1.8)                3 (2.3)             0 (0)                    0 (0)               0.73                          0.62   1.00
  Left anterior descending artery                                   748 (47.5)              66 (50.4)           39 (59.1)                27 (50)             0.53                          0.08   0.78
  Left circumflex artery                                            301 (19.1)              22 (16.8)           13 (19.7)                6 (11.1)            0.56                          0.87   0.16
  Right coronary artery                                             676 (42.9)              59 (45)             25 (37.9)                29 (53.7)           0.65                          0.45   0.13
  Saphenous vein graft                                              9 (0.6)                 0 (0)               0 (0)                    0 (0)               1.00                          1.00   1.00
  Number of stents per lesion                                       1.33±0.61               1.32±0.60           1.33±0.61                1.30±0.65           0.89                          0.97   0.73
  Type of stent per lesion[a](#jah33138-note-0008){ref-type="fn"}                                                                                                                                 
  First‐generation DES                                              27 (1.3)                1 (0.6)             0 (0)                    0 (0)               0.42                          0.62   0.62
  New‐generation DES                                                1740 (82.9)             158 (89.3)          62 (73.8)                62 (80.5)           0.04                          0.09   0.65
  BMS                                                               339 (16.2)              17 (9.6)            22 (26.2)                16 (20.8)           0.03                          0.05   0.36
  Total stent length per lesion (mm)                                27.2±14.6               29.1±16.1           25.3±12.9                26.2±12.5           0.10                          0.27   0.57
  Minimum stent diameter per lesion (mm)                            3.05±0.52               3.04±0.51           3.03±0.51                3.05±0.48           0.84                          0.97   0.96
  Thrombus aspiration                                               890 (40.3)              75 (39.9)           34 (35.1)                31 (37.8)           0.93                          0.33   0.68
  Bifurcation lesion (any lesion)                                   229 (14.5)              22 (16.8)           11 (16.7)                8 (14.8)            0.52                          0.60   1.00
  Long lesion[b](#jah33138-note-0009){ref-type="fn"}                249 (23.6)              19 (23.8)           7 (16.7)                 11 (28.9)           1.00                          0.36   0.44

BMS indicates bare‐metal stent; DES, drug‐eluting stent.

First‐generation DES: Cypher, Endeavour. Totals for types of stent do not sum up to the number of total stents, because 7 lesions were treated with both new‐generation DES and BMS.

Any total stent length ≥20 mm.

###### 

Multivariate Predictors of Any Prasugrel Cessation

                                     n      HR (95% CI)          *P* Value
  ---------------------------------- ------ -------------------- -----------
  Female sex                         1619   1.63 (1.20--2.23)    0.002
  History of cerebrovascular event   1619   3.88 (1.44--10.46)   0.007
  Age (per 10 y)                     1619   1.15 (1.02--1.31)    0.024

CI indicates confidence interval; HR, hazard ratio.

Reasons for Prasugrel Cessation {#jah33138-sec-0017}
-------------------------------

Patient‐reported reasons for early prasugrel cessation are illustrated in Figure [3](#jah33138-fig-0003){ref-type="fig"}. Leading reasons for crossover included unspecified reason, oral anticoagulation initiation, bleeding, interventions, and perceived side effects. Reasons for discontinuation were unspecified physician recommendation, oral anticoagulation initiation, and interventions. Leading reasons for disruption were patient preference, bleeding, side effects, and treatment cost (Figure [3](#jah33138-fig-0003){ref-type="fig"}).

![Patient‐reported reasons for early prasugrel cessation (crossover, physician‐recommended discontinuation, and disruption). OAC indicates oral anticoagulation.](JAH3-7-e008085-g003){#jah33138-fig-0003}

Clinical Outcomes in Relation to Early Prasugrel Cessation {#jah33138-sec-0018}
----------------------------------------------------------

At 1 year, the primary end point had occurred in 95 patients (5.2%) (Table [4](#jah33138-tbl-0004){ref-type="table"}). Figure [4](#jah33138-fig-0004){ref-type="fig"} summarizes 1‐year clinical outcomes in patients without cessation (reference) compared with events occurring after any type of early prasugrel cessation. The primary end point occurred more frequently following disruption (HR: 3.04, 95% CI, 1.34--6.91; *P*=0.008). Differences were consistent for the key secondary end point (HR: 2.39, 95% CI, 1.12--5.10; *P*=0.03), all‐cause death (HR: 8.08, 95% CI, 3.05--21.37; *P*\<0.001), cardiac death (HR: 7.35, 95% CI, 2.48--21.80; *P*\<0.001), MI (HR: 4.00, 95% CI, 1.61--9.94; *P*=0.003), and definite or probable stent thrombosis (HR: 2.96, 95% CI, 1.08--8.12; *P*=0.03). No significant differences were observed following discontinuation or crossover for the primary or secondary end points. There was no association between early treatment cessation and subsequent bleeding events (Figure [S1](#jah33138-sup-0001){ref-type="supplementary-material"}). Table [S5](#jah33138-sup-0001){ref-type="supplementary-material"} summarizes individual primary end point events following any mode of early prasugrel cessation. Median time from prasugrel cessation to first primary end point event was 10 days following crossover, 35 days following discontinuation, and 8 days following disruption.

###### 

Incidence of Adverse Clinical Events Within 1 Year

                              No Cessation (n=1578)   Crossover (n=131)   Discontinuation (n=67)   Disruption (n=54)
  --------------------------- ----------------------- ------------------- ------------------------ -------------------
  Primary end point           65 (4.1)                13 (9.9)            9 (13.4)                 8 (14.8)
  Secondary end point         100 (6.3)               21 (16.1)           12 (17.9)                9 (16.7)
  Death                       26 (1.6)                1 (0.8)             2 (3.0)                  5 (9.3)
  Cardiac death               23 (1.5)                1 (0.8)             2 (3.0)                  4 (7.5)
  Myocardial infarction       40 (2.5)                8 (6.1)             3 (4.5)                  5 (9.3)
  Spontaneous MI              16 (1.0)                5 (3.8)             1 (1.5)                  3 (5.7)
  Death or MI                 63 (4.0)                9 (6.9)             5 (7.6)                  6 (10.9)
  Stroke                      5 (0.3)                 4 (3.1)             4 (6)                    2 (3.8)
  TVR                         63 (4.0)                10 (7.7)            7 (10.5)                 5 (9.4)
  Definite stent thrombosis   25 (1.6)                3 (2.3)             2 (3.0)                  4 (7.6)
  BARC 3 to 5 bleeding        41 (2.6)                14 (10.7)           5 (7.5)                  6 (11.5)
  BARC 3                      40 (2.6)                11 (8.4)            4 (6)                    6 (11.5)
  BARC 4                      0 (0.0)                 3 (2.3)             1 (1.5)                  0 (0.0)
  BARC 5                      1 (0.1)                 0 (0.0)             0 (0.0)                  0 (0.0)
  TIMI major bleeding         21 (1.3)                11 (8.4)            3 (4.5)                  5 (9.6)
  TIMI minor bleeding         21 (1.3)                3 (2.3)             3 (4.5)                  0 (0.0)

Counted are first events per event type per patient (% from Kaplan--Meier estimate). Cumulative incidence within 1 year following index PCI is presented, regardless of event occurrence before or following prasugrel cessation in patients with crossover, discontinuation, or disruption. Primary end point was a composite of cardiac death, nonfatal MI, and stroke. Secondary end point was a composite of cardiac death, MI, stroke, TVR, and definite or probable stent thrombosis. BARC indicates Bleeding Academic Research Consortium; MI, myocardial infarction; PCI, percutaneous coronary intervention; TIMI, Thrombolysis in Myocardial Infarction; TVR, target vessel revascularization.

![Risk of clinical outcomes following early prasugrel cessation: crossover (n=131); discontinuation (n=67); and disruption (n=54). Results of time‐dependent Cox model analyses for the risk of the primary and secondary end points. Presented are numbers of observed events (from Kaplan--Meier estimate), hazard ratios (HRs), and respective 95% confidence intervals (CI). The observed vs expected number of events are presented for each period, where expected numbers were calculated as number of events divided by the HR (compared with the reference of being on prasugrel treatment). The primary end point was a composite of cardiac death, nonfatal myocardial infarction (MI), and stroke. Secondary end point was a composite of cardiac death, MI, stroke, target‐vessel revascularization (TVR), and definite or probable stent thrombosis.](JAH3-7-e008085-g004){#jah33138-fig-0004}

Sensitivity Analyses: RCT Versus Registry Patients {#jah33138-sec-0019}
--------------------------------------------------

Patients enrolled in the RCT (n=484, 26.4%) had a lower rate of prior PCI and less frequently presented with Killip class IV, with otherwise nondiffering baseline characteristics compared with patients enrolled in the registries (n=1346, 73.6%) (Table [S6](#jah33138-sup-0001){ref-type="supplementary-material"}). The frequency of overall vprasugrel cessation as well as of each type of cessation did not differ significantly between patients enrolled in the RCT versus the registries (Table [S7](#jah33138-sup-0001){ref-type="supplementary-material"}). Consistent with the findings in the entire pooled population, disruption, but not crossover or discontinuation, was associated with higher risk of the primary and secondary end points, MI, all‐cause and cardiac mortality at 1 year in a sensitivity analysis focusing only on patients included in the registries (Figure [S2](#jah33138-sup-0001){ref-type="supplementary-material"}).

Discussion {#jah33138-sec-0020}
==========

While current recommendations advocate DAPT for 1 year following acute MI, there is limited evidence regarding adherence to prasugrel---one of the preferred antiplatelet agents in this context. This study assessed the incidence, reasons, and clinical impact of early prasugrel cessation in a sizable, contemporary cohort of patients with STEMI treated with PCI by current standards. Prasugrel cessation before 1 year was not uncommon (≈14%), but was less frequent compared with previous studies focusing on any DAPT cessation post‐PCI in more stable clinical settings.[6](#jah33138-bib-0006){ref-type="ref"}, [7](#jah33138-bib-0007){ref-type="ref"}, [8](#jah33138-bib-0008){ref-type="ref"}, [9](#jah33138-bib-0009){ref-type="ref"}, [10](#jah33138-bib-0010){ref-type="ref"} Crossover to another P2Y~12~‐inhibitor, mainly clopidogrel, was more frequent compared with physician‐recommended discontinuation or disruption (because of bleeding, side effects, or noncompliance). Clinical characteristics previously linked to higher bleeding risk[18](#jah33138-bib-0018){ref-type="ref"} were more common in patients who stopped prasugrel, suggesting that concerns about bleeding likely influenced decision‐making regarding antiplatelet management. Even though the rate of major adverse cardiac events was numerically higher following discontinuation, disruption was the only mode of early prasugrel cessation associated with a statistically significant adverse impact on subsequent cardiovascular outcomes.

Rapid mechanical reperfusion with coronary stenting and potent adjunctive antithrombotic treatment are the principles for optimal management of patients with STEMI. Prasugrel, a potent and rapid‐acting thienopyridine, is more effective than clopidogrel for prevention of ischemic events in patients with MI including those with STEMI.[4](#jah33138-bib-0004){ref-type="ref"}, [19](#jah33138-bib-0019){ref-type="ref"} Current guidelines recommend 12‐month DAPT consisting of aspirin and a P2Y~12~‐inhibitor, preferably prasugrel or ticagrelor unless contraindicated.[1](#jah33138-bib-0001){ref-type="ref"}, [2](#jah33138-bib-0002){ref-type="ref"} In this study, 86% of patients with STEMI remained on continuous prasugrel treatment within 1 year following PCI. Considering that more than half of early prasugrel cessations involved switching to another P2Y~12~‐inhibitor and in conjunction with high adherence to aspirin, our findings show adherence to guideline‐recommended DAPT duration in \>90% of patients. This finding likely reflects appreciation of the persistently elevated ischemic risk following acute STEMI. Previous investigations reported higher rates of early DAPT cessation within 1 year post PCI, ranging between 18.5% and 24%,[6](#jah33138-bib-0006){ref-type="ref"}, [7](#jah33138-bib-0007){ref-type="ref"}, [8](#jah33138-bib-0008){ref-type="ref"}, [9](#jah33138-bib-0009){ref-type="ref"}, [10](#jah33138-bib-0010){ref-type="ref"} but this needs to be interpreted in view of different study populations (primarily stable patients with CAD) and antiplatelet treatments (mostly clopidogrel) as well as varying definitions of treatment cessation across studies.

Analyses of correlates and underlying reasons for prasugrel cessation provided additional important insights. Crossover to clopidogrel---the most common pattern of cessation---occurred more frequently among older, female patients with a history of malignancy or prior cerebrovascular event (ie, a formal contraindication for prasugrel). Age and female sex previously emerged as independent predictors of bleeding in prasugrel‐treated patients.[18](#jah33138-bib-0018){ref-type="ref"} Along these lines, it is important to note that the superior efficacy of prasugrel over clopidogrel for reduction of ischemic events was coupled with excess bleeding in the overall population,[4](#jah33138-bib-0004){ref-type="ref"} but not in the prespecified STEMI subanalysis of the TRITON‐TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel‐Thrombolysis In Myocardial Infarction 38) trial.[19](#jah33138-bib-0019){ref-type="ref"} The finding that oral anticoagulation initiation was a main reason for crossover or discontinuation is consistent with evidence of unacceptably high bleeding risk attributed to triple antithrombotic therapy including prasugrel.[20](#jah33138-bib-0020){ref-type="ref"} Collectively these findings likely reflect physician consideration of bleeding risk factors that may have led to change from prasugrel to a less‐potent antiplatelet agent. Conversely, with the exception of insulin‐treated diabetes mellitus, we did not observe a greater cluster of well‐recognized "ischemic" risk factors (eg, smoking, prior MI or PCI, graft stenting, and disease complexity[21](#jah33138-bib-0021){ref-type="ref"}) in patients who remained on prasugrel during 1 year.

Previous studies assessing clinical outcomes in relation to early DAPT cessation in more stable clinical settings have yielded conflicting results. Several reports found no adverse impact of DAPT interruptions after 30 days post PCI with new‐generation DES[9](#jah33138-bib-0009){ref-type="ref"}, [10](#jah33138-bib-0010){ref-type="ref"}; these studies, however, pooled all DAPT interruptions between 30 days and 12 months, thereby not accounting for the possibly differing ischemic risk throughout the entire period following the first month post‐PCI. Other studies applying time‐dependent analyses reported higher risk of ischemic events following early DAPT cessation[7](#jah33138-bib-0007){ref-type="ref"}, [8](#jah33138-bib-0008){ref-type="ref"} and importantly showed that the clinical sequelae depend on the underlying reason and mode of cessation.[6](#jah33138-bib-0006){ref-type="ref"} Our present findings extend these observations in the very high‐risk setting of patients with STEMI by demonstrating a lack of association between prasugrel discontinuation or crossover and greater ischemic risk. In contrast, prasugrel disruption was associated with 3‐fold higher risk of major ischemic adverse events and consistently higher rates of mortality and stent thrombosis. Although direct comparisons are hindered by differing end point definitions, the incremental risk of major ischemic events following prasugrel disruption in STEMI appears to be greater compared with the respective risk following DAPT disruption in stable CAD or ACS patients in the PARIS registry[6](#jah33138-bib-0006){ref-type="ref"} (HR 2.97 in this study versus 1.5 in PARIS). Notwithstanding these associations disfavoring disruption, early prasugrel cessation (by any mode) accounted for only a small proportion of all ischemic events within the first year following STEMI, since \>80% of these events occurred on prasugrel treatment.

The leading cause of prasugrel disruption was cessations because of unjustified patient decision (ie, noncompliance). We did not detect clinical characteristics that could allow early identification of these patients. In view of the adverse clinical impact of disruption, our findings emphasize the need to continuously promote patient education and enhance compliance with recommended antiplatelet treatment following STEMI. Moreover, the link between bleeding, prasugrel disruption, and increased risk of downstream ischemic events in this study substantiates the concept that bleeding complications adversely impact long‐term PCI outcomes at least in part by triggering early withdrawal of recommended antiplatelet treatment.

Recent recommendations advocate 12‐month adherence to the combination of aspirin plus a (preferably potent) P2Y~12~‐inhibitor following primary PCI, but indicate that earlier discontinuation may be considered in patients at high risk of bleeding.[22](#jah33138-bib-0022){ref-type="ref"} While limited by the observational nature of the study and relatively small number of events, our findings lend support to these Class IIb recommendations (which were based on limited data) by showing no excess ischemic risk in patients who discontinued prasugrel or changed to a less‐potent agent based on justified medical decision (presumably related, at least in part, to higher bleeding risk). Along the same lines, a focused guideline update by the European Society of Cardiology recommended that in patients with ACS at high risk of bleeding, discontinuation of P2Y12‐inhibitor therapy after 6 months post‐stenting should be considered, as the risk of ischemic complication is highest immediately after the index event and then gradually declines.[23](#jah33138-bib-0023){ref-type="ref"} These recommendations were based on studies including primarily non‐ST segment elevation--ACS patients treated with clopidogrel,[24](#jah33138-bib-0024){ref-type="ref"} and the need for further studies focusing on novel P2Y12 inhibitors was explicitly acknowledged.[23](#jah33138-bib-0023){ref-type="ref"} Properly designed prospective studies are needed to assess tailored approaches for defining the potency and duration of antiplatelet therapy following STEMI, accounting for individual‐patient bleeding and ischemic risk.

The TROPICAL ACS (Testing Responsiveness To Platelet Inhibition On Chronic Antiplatelet Treatment For Acute Coronary Syndromes) randomized trial recently showed that platelet function‐guided de‐escalation of prasugrel to clopidogrel 14 days after hospital discharge was noninferior to 1‐year treatment with prasugrel in terms of net clinical benefit in patients with ACS.[25](#jah33138-bib-0025){ref-type="ref"} In the TOPIC (Timing of Platelet Inhibition After Acute Coronary Syndrome) randomized study (including 646 ACS patients, 40% with STEMI), de‐escalation of prasugrel or ticagrelor to clopidogrel 1 month post index event was superior to 1‐year treatment with a potent agent for prevention of bleeding complications, without increase in ischemic events.[26](#jah33138-bib-0026){ref-type="ref"} In the present observational analysis, we found no increase in ischemic events following crossover (including primarily de‐escalation to clopidogrel and occurring at a median of 31 days post index PCI) compared with continued prasugrel treatment throughout 1 year.

The TRANSLATE‐ACS registry reported early cessation of clopidogrel or prasugrel in 21% of STEMI or NSTE‐ACS patients within 1‐year post PCI.[27](#jah33138-bib-0027){ref-type="ref"} Notably, that registry did not capture crossover, although this is not uncommon in clinical practice among patients treated with potent antiplatelet agents and was in fact the most common mode of prasugrel cessation in our analysis. Thienopyridine cessation (not including crossover) was substantially more common in TRANSLATE ACS compared with the present study (21% versus 6.3%, ie, the sum of discontinuation and disruption in our study). Whether this difference might reflect variations in practice patterns in the United States versus Europe (as suggested, for example, by considerable differences in the use of bare‐metal stent versus DES in the 2 studies) or relate to more contemporary treatment patterns in the present analysis (enrollment extended up to 2014 versus 2012 in TRANSLATE‐ACS) cannot be definitively addressed. Of note, real‐world observations indicate greater acceptance rates and a steady increase in the use of prasugrel over time.[5](#jah33138-bib-0005){ref-type="ref"}, [28](#jah33138-bib-0028){ref-type="ref"} Any thienopyridine cessation was associated with an increased risk of major adverse cardiac events in TRANSLATE ACS,[27](#jah33138-bib-0027){ref-type="ref"} which contrast with our present findings in a STEMI cohort as well as the findings of the PARIS registry[6](#jah33138-bib-0006){ref-type="ref"} in a broader PCI population.

This study has several limitations. First, the study was not designed to evaluate clinical outcomes in relation to prasugrel treatment; however, adverse events were prospectively defined outcome measures and were specifically evaluated during 1‐year follow‐up in all 3 studies, and adherence to medical treatment was assessed at predefined time‐points applying standardized definitions. Second, the present cohort pooled patients from 2 prospective, all‐comers registries and a randomized STEMI trial. However, the COMFORTABLE‐AMI trial had a broadly inclusive design with minimal exclusion criteria; in addition, identical follow‐up procedures and independent clinical event adjudication were applied in the randomized trial as in the registries, thereby minimizing patient heterogeneity in the present pooled cohort. Although some differences in study design and patient characteristics did exist, our sensitivity analyses focusing only on registry patients (Figure [S2](#jah33138-sup-0001){ref-type="supplementary-material"}) showed consistent outcomes as in the entire pooled population. Despite the sizable STEMI cohort, this study may be underpowered to assess clinical outcomes in relation to different modes of prasugrel cessation; in particular, discontinuation was associated with a numerically (1.6‐fold) higher risk of major adverse cardiac events, which nonetheless did not reach statistical significance, likely because of the small numbers of patients and limited numbers of events in each group. Unlike the PARIS study,[6](#jah33138-bib-0006){ref-type="ref"} the exact timing of possible prasugrel re‐initiation was not consistently captured in this study; therefore, temporary interruptions (eg, before surgery) could not be defined separately but were included under physician‐determined discontinuation. While the association between prasugrel cessation and subsequent events is substantiated by being derived from time‐varying analyses, the fact that no other covariates were considered is acknowledged as a limitation. Finally, the findings of this observational study are presented as hypothesis‐generating only; prospective, adequately powered studies are required to assess outcomes in relation to shorter than currently recommended prasugrel treatment duration in the high‐risk setting of STEMI.

Conclusions {#jah33138-sec-0021}
===========

Prasugrel cessation was observed in 1 of 7 patients with STEMI within 1 year following primary PCI in this contemporary study. Early cessation involved primarily change to another P2Y~12‐~inhibitor and was predicted by clinical characteristic portending higher bleeding risk. Prasugrel disruption (because of bleeding, side effects, or noncompliance) was associated with a statistically significant, 3‐fold higher risk of major ischemic events.
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**Figure S1.** Risk of bleeding in relation to early prasugrel cessation: crossover (n=131); discontinuation (n=67); and disruption (n=54). Presented are numbers of observed events (from Kaplan--Meier estimate), expected events, hazard ratios, and respective 95% confidence intervals (CI).

**Figure S2.** Results of time‐dependent Cox model analyses for the risk of adverse clinical outcomes following early prasugrel cessation (crossover: n=107; discontinuation; n=53; disruption: n=36) in a sensitivity analysis including only patients enrolled in the observational registries (Bern PCI Registry and SPUM‐ACS study; n=1346). Presented are numbers of observed events (from Kaplan--Meier estimate), expected events, hazard ratios (HRs), and respective 95% confidence intervals (CI). The observed versus expected number of events are presented for each period, where expected numbers were calculated as number of events divided by the HR (compared with the reference of being on prasugrel treatment).
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